The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice
Open accessAbstract
Peripheral polyneuropathy is a common and dose-limiting side effect of many important chemotherapeutic agents. Most such neuropathies are characterized by early axonal degeneration, yet therapies that inhibit this axonal destruction process do not currently exist. Recently, we and others discovered that genetic deletion of SARM1 (sterile alpha and TIR motif containing protein 1) dramatically protects axons from degeneration after axotomy in mice. This finding fuels hope that inhibition of SARM1 or its downstream components can be used therapeutically in patients threatened by axonal loss. However, axon loss in most neuropathies, including chemotherapy-induced peripheral neuropathy, is the result of subacute/chronic processes that may be regulated differently than the acute, one time insult of axotomy. Here we evaluate if genetic deletion of SARM1 decreases axonal degeneration in a mouse model of neuropathy induced by the chemotherapeutic agent vincristine. In wild-type mice, 4 weeks of twice-weekly intraperitoneal injections of 1.5 mg/kg vincristine cause pronounced mechanical and heat hyperalgesia, a significant decrease in tail compound nerve action potential amplitude, loss of intraepidermal nerve fibres and significant degeneration of myelinated axons in both the distal sural nerve and nerves of the toe. Neither the proximal sural nerve nor the motor tibial nerve exhibit axon loss. These findings are consistent with the development of a distal, sensory predominant axonal polyneuropathy that mimics vincristine-induced peripheral polyneuropathy in humans. Using the same regimen of vincristine treatment in SARM1 knockout mice, the development of mechanical and heat hyperalgesia is blocked and the loss in tail compound nerve action potential amplitude is prevented. Moreover, SARM1 knockout mice do not lose unmyelinated fibres in the skin or myelinated axons in the sural nerve and toe after vincristine. Hence, genetic deletion of SARM1 blocks the development of vincristine-induced peripheral polyneuropathy in mice. Our results reveal that subacute/chronic axon loss induced by vincristine occurs via a SARM1 mediated axonal destruction pathway, and that blocking this pathway prevents the development of vincristine-induced peripheral polyneuropathy. These findings, in conjunction with previous studies with axotomy and traumatic brain injury, establish SARM1 as the central determinant of a fundamental axonal degeneration pathway that is activated by diverse insults. We suggest that targeting SARM1 or its downstream effectors may be a viable therapeutic option to prevent vincristine-induced peripheral polyneuropathy and possibly other peripheral polyneuropathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative assessment of tactile allodynia in the rat paw
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90144-9 · Cited by 7,697
Efficient Analysis of Experimental Observations
Dixon, W. J. (1980) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.20.040180.002301 · Cited by 2,208
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060
Self-citationdSarm/Sarm1 Is Required for Activation of an Injury-Induced Axon Death Pathway
Osterloh, J. M., Yang, J., Rooney, T. M., Fox, A. N., Adalbert, R., Powell, E. H., Sheehan, A. E., Avery, M. A., Hackett, R., Logan, M. A., et al. (2012) · Science · doi:10.1126/science.1223899 · Cited by 687
Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve
Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H., & Gordon, S. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00771.x · Cited by 646 · cited 2×
“The discovery of Wallerian degeneration slow (Wlds) mutant mice, in which axonal degeneration is greatly delayed after traumatic injury, revealed that axonal degeneration indeed can be blocked (Lunn et al., 1989).”
BackgroundWallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene
Mack, T. G. A., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001) · Nature Neuroscience · doi:10.1038/nn770 · Cited by 611
SARM1 activation triggers axon degeneration locally via NAD + destruction
Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2015) · Science · doi:10.1126/science.1258366 · Cited by 593
Self-citationEndogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons
Gilley, J., & Coleman, M. P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000300 · Cited by 472 · cited 1×
“NMNAT2 is essential for axon survival, as the loss of NMNAT2 is sufficient to induce SARM1-dependent axonal degeneration in the absence of axonal injury (Gilley and Coleman, 2010; Gilley et al., 2015).”
BackgroundAxon degeneration: Molecular mechanisms of a self-destruction pathway
Wang, J. T., Medress, Z. A., & Barres, B. A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201108111 · Cited by 442
Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?
Carozzi, V. A., Canta, A., & Chiorazzi, A. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.014 · Cited by 431
Wu, G., Ringkamp, M., Hartke, T. V., Murinson, B. B., Campbell, J. N., Griffin, J. W., & Meyer, R. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-j0002.2001 · Cited by 427
Sarm1-Mediated Axon Degeneration Requires Both SAM and TIR Interactions
Gerdts, J., Summers, D. W., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1197-13.2013 · Cited by 375
Self-citationAxon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism
Gerdts, J., Summers, D. W., Milbrandt, J., & DiAntonio, A. (2016) · Neuron · doi:10.1016/j.neuron.2015.12.023 · Cited by 320
Self-citationSIAU, C., XIAO, W., & BENNETT, G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.05.007 · Cited by 300
Vincristine‐induced neuropathy: A clinical study of fifty leukemic patients
Sandier, S. G., Tobin, W., & Henderson, E. S. (1969) · Neurology · doi:10.1212/wnl.19.4.367 · Cited by 300
Pathological Axonal Death through a MAPK Cascade that Triggers a Local Energy Deficit
Yang, J., Wu, Z., Renier, N., Simon, D. J., Uryu, K., Park, D. S., Greer, P. A., Tournier, C., Davis, R. J., & Tessier-Lavigne, M. (2015) · Cell · doi:10.1016/j.cell.2014.11.053 · Cited by 294
Beirowski, B., Adalbert, R., Wagner, D., Grumme, D. S., Addicks, K., Ribchester, R. R., & Coleman, M. P. (2005) · BMC Neuroscience · doi:10.1186/1471-2202-6-6 · Cited by 293
VINCRISTINE NEUROPATHY: CLINICAL AND ELECTROPHYSIOLOGICAL OBSERVATIONS
CASEY, E. B., JELLIFE, A. M., LE QUESNE, P. M., & MILLETT, Y. L. (1973) · Brain · doi:10.1093/brain/96.1.69 · Cited by 293
Wu, G., Ringkamp, M., Murinson, B. B., Pogatzki, E. M., Hartke, T. V., Weerahandi, H. M., Campbell, J. N., Griffin, J. W., & Meyer, R. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-17-07746.2002 · Cited by 279
Diouf, B., Crews, K. R., Lew, G., Pei, D., Cheng, C., Bao, J., Zheng, J. J., Yang, W., Fan, Y., Wheeler, H. E., et al. (2015) · JAMA · doi:10.1001/jama.2015.0894 · Cited by 278
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
Argyriou, A., Kyritsis, A., Makatsoris, T., & Kalofonos, H. (2014) · Cancer Management and Research · doi:10.2147/cmar.s44261 · Cited by 273
Koss, M. N., Hochholzer, L., & O’Leary, T. J. (1991) · Cancer · doi:10.1002/1097-0142(19910501)67:9<2241::aid-cncr2820670905>3.0.co;2-a · Cited by 272
The neuromyopathy of vincristine in man
Bradley, W. G., Lassman, L. P., Pearce, G. W., & Walton, J. N. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90013-4 · Cited by 261
P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD Salvage
Wang, G., Han, T., Nijhawan, D., Theodoropoulos, P., Naidoo, J., Yadavalli, S., Mirzaei, H., Pieper, A. A., Ready, J. M., & McKnight, S. L. (2014) · Cell · doi:10.1016/j.cell.2014.07.040 · Cited by 243
MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival
Kim, Y., Zhou, P., Qian, L., Chuang, J.-Z., Lee, J., Li, C., Iadecola, C., Nathan, C., & Ding, A. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070868 · Cited by 234
LaPointe, N. E., Morfini, G., Brady, S. T., Feinstein, S. C., Wilson, L., & Jordan, M. A. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.05.008 · Cited by 219
Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
Owellen, R. J., Hartke, C., Dickerson, R. M., & Hains, F. O. (1976) · PubMed · Cited by 207
Lavoie Smith, E. M., Li, L., Chiang, C., Thomas, K., Hutchinson, R. J., Wells, E. M., Ho, R. H., Skiles, J., Chakraborty, A., Bridges, C. M., et al. (2015) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12114 · Cited by 198
Absence of SARM1 Rescues Development and Survival of NMNAT2-Deficient Axons
Gilley, J., Orsomando, G., Nascimento-Ferreira, I., & Coleman, M. P. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.060 · Cited by 197
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening
Verstappen, C. C. P., Koeppen, S., Heimans, J. J., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000154642.45474.28 · Cited by 196
Henninger, N., Bouley, J., Sikoglu, E. M., An, J., Moore, C. M., King, J. A., Bowser, R., Freeman, M. R., & Brown, R. H. (2016) · Brain · doi:10.1093/brain/aww001 · Cited by 196
Topp, K. S., Tanner, K. D., & Levine, J. D. (2000) · The Journal of Comparative Neurology · doi:10.1002/1096-9861(20000904)424:4<563::aid-cne1>3.0.co;2-u · Cited by 189
Tanner, K. D., Levine, J. D., & Topp, K. S. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980615)395:4<481::aid-cne5>3.0.co;2-y · Cited by 188
An 85-kb tandem triplication in the slow Wallerian degeneration ( Wld s ) mouse
Coleman, M. P., Conforti, L., Buckmaster, E. A., Tarlton, A., Ewing, R. M., Brown, M. C., Lyon, M. F., & Perry, V. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9985 · Cited by 188
Wang, J., Gines, S., MacDonald, M. E., & Gusella, J. F. (2005) · BMC Neuroscience · doi:10.1186/1471-2202-6-1 · Cited by 179
Toxic neuropathy in patients with pre-existing neuropathy
Chaudhry, V., Chaudhry, M., Crawford, T. O., Simmons-O’Brien, E., & Griffin, J. W. (2003) · Neurology · doi:10.1212/01.wnl.0000043691.53710.53 · Cited by 173
Weng, R. H., Cordella, V. J., & Dougherty, M. P. (2003) · Pain · doi:10.1016/s0304-3959(02)00445-1 · Cited by 161 · cited 2×
“, 1998b, 2003) and wide dynamic range neurons in the spinal cord exhibit increased spontaneous activity (Weng et al., 2003).”
BackgroundBoehmerle, W., Huehnchen, P., Peruzzaro, S., Balkaya, M., & Endres, M. (2014) · Scientific Reports · doi:10.1038/srep06370 · Cited by 159
Szretter, K. J., Samuel, M. A., Gilfillan, S., Fuchs, A. G., Colonna, M., & Diamond, M. S. (2009) · Journal of Virology · doi:10.1128/jvi.00836-09 · Cited by 159
Ezendam, N. P. M., Pijlman, B. M., Bhugwandass, C., Pruijt, H., Mols, F., Vos, M. C., Pijnenborg, J. M. A., & van de Poll-Franse, L. V. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.09.016 · Cited by 158
Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine
Boyette-Davis, J. A., Cata, J. P., Driver, L. C., Novy, D. M., Bruel, B. M., Mooring, D. L., Wendelschafer-Crabb, G., Kennedy, W. R., & Dougherty, P. M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2047-z · Cited by 148
Wlds mice are resistant to paclitaxel (taxol) neuropathy
Wang, M. S., Davis, A. A., Culver, D. G., & Glass, J. D. (2002) · Annals of Neurology · doi:10.1002/ana.10300 · Cited by 146
Milde, S., Gilley, J., & Coleman, M. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001539 · Cited by 138
Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease
Jesús‐Cortés, H. D., Xu, P., Drawbridge, J., Estill, S. J., Huntington, P. J., Tran, S., Britt, J. K., Tesla, R., Morlock, L., Naidoo, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213956109 · Cited by 132
Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis
Tesla, R., Wolf, H. P., Xu, P., Drawbridge, J., Estill, S. J., Huntington, P., McDaniel, L., Knobbe, W., Burket, A., Tran, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213960109 · Cited by 129
Ebenezer, G. J., McArthur, J. C., Thomas, D., Murinson, B. B., Hauer, P., Polydefkis, M. J., & Griffin, J. W. (2007) · Brain · doi:10.1093/brain/awm199 · Cited by 128
Chen, C.-Y., Lin, C.-W., Chang, C.-Y., Jiang, S., & Hsueh, Y. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201008050 · Cited by 127
Yin, T. C., Britt, J. K., Jesús‐Cortés, H. D., Lü, Y., Genova, R. M., Khan, M. Z., Voorhees, J. R., Shao, J., Katzman, A. C., Huntington, P. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.030 · Cited by 125
Nociceptor Hyper-Responsiveness during Vincristine-Induced Painful Peripheral Neuropathy in the Rat
Tanner, K. D., Reichling, D. B., & Levine, J. D. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-16-06480.1998 · Cited by 123
A New Animal Model of Vincristine-Induced Nociceptive Peripheral Neuropathy
Authier, N., Gillet, J.-P., Fialip, J., Eschalier, A., & Coudoré, F. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00043-3 · Cited by 120
Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas
Haim, N., Epelbaum, R., Ben-Shahar, M., Yarnitsky, D., Simri, W., & Robinson, E. (1994) · Cancer · Cited by 115
Wang, M. S., Fang, G., Culver, D. G., Davis, A. A., Rich, M. M., & Glass, J. D. (2001) · Annals of Neurology · doi:10.1002/ana.10039 · Cited by 90
Shen, Y., Zhang, Z., Zhu, M.-D., Jiang, B., Yang, T., & Gao, Y. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.012 · Cited by 77
Lin, C.-W., & Hsueh, Y. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.12.002 · Cited by 59
Chemotherapy-induced peripheral neuropathies in hematological malignancies
Jongen, J. L. M., Broijl, A., & Sonneveld, P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1632-x · Cited by 59
Kamei, J., Tamura, N., & Saitoh, A. (2005) · Pain · doi:10.1016/j.pain.2005.05.026 · Cited by 47
Tanner, K. D., Reichling, D. B., Gear, R. W., Paul, S. M., & Levine, J. D. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00023-x · Cited by 45
Massoll, C., Mando, W., & Chintala, S. K. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10973 · Cited by 42
Early phase of vincristine neuropathy in man
Guihéneuc, P., Ginet, J. D., Groleau, J. Y., & Rojouan, J. (1980) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(80)90179-3 · Cited by 38
Chemotherapy-induced peripheral neuropathies: an integrative review of the literature
Costa, T. C., Lopes, M., dos Anjos, A. C. Y., & Zago, M. M. F. (2015) · Revista da Escola de Enfermagem da USP · doi:10.1590/s0080-623420150000200020 · Cited by 36
Thibault, K., Rivals, I., M’Dahoma, S., Dubacq, S., Pezet, S., & Calvino, B. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0095-4 · Cited by 25
Bruna, J., Alé, A., Velasco, R., Jaramillo, J., Navarro, X., & Udina, E. (2011) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2011.00346.x · Cited by 22
Suppressive Effect of Imipramine on Vincristine-Induced Mechanical Allodynia in Mice
Saika, F., Kiguchi, N., Kobayashi, Y., Fukazawa, Y., Maeda, T., Ozaki, M., & Kishioka, S. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1231 · Cited by 17
Liew, E., Thyagu, S., Atenafu, E. G., Alibhai, S. M. H., & Brandwein, J. M. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.09.018 · Cited by 12
Cited by
Chemotherapy-induced peripheral neuropathy: a current review
Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017) · Annals of Neurology · doi:10.1002/ana.24951 · Cited by 908
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061451 · Cited by 829
Essuman, K., Summers, D. W., Sasaki, Y., Mao, X., DiAntonio, A., & Milbrandt, J. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.022 · Cited by 619
Self-citationSARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration
Figley, M. D., Gu, W., Nanson, J. D., Shi, Y., Sasaki, Y., Cunnea, K., Malde, A. K., Jia, X., Luo, Z., Saikot, F. K., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.02.009 · Cited by 324
Self-citationProgrammed axon degeneration: from mouse to mechanism to medicine
Coleman, M. P., & Höke, A. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0269-3 · Cited by 321
Metadata
- Authors
- Geisler, S., Doan, R. A., Strickland, A., Huang, X., Milbrandt, J., & DiAntonio, A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-25
- Volume
- 139
- Issue
- 12
- Pages
- 3092-3108
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2537687146
- Cited by
- 270
- References
- 64
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.